PD-1抗体-话题@MedSci

#PD-1抗体#

44篇内容 | 2888人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2212718, encodeId=05ce2212e18ff, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a> <a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a> <a href='/topic/show?id=d6fb5413f0' target=_blank style='color:#2F92EE;'>#CTLA-4抗体#</a> <a href='/topic/show?id=5120109694f4' target=_blank style='color:#2F92EE;'>#双免疫治疗#</a>, objectTitle=大咖谈 | 双免疫联合治疗的机制和研究进展, objectType=article, longId=831199, objectId=7a2c83119995, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240701/1719825954170_5579292.png, objectUrl=/article/show_article.do?id=7a2c83119995, replyNumber=0, likeNumber=118, createdTime=2024-07-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7a2c83119995, moduleTitle=大咖谈 | 双免疫联合治疗的机制和研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a2c83119995)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1577115, encodeId=b86915e71155f, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Cell Chemical Biology：上科大仓勇团队发现分子胶可增强PD-1抗体肿瘤免疫疗效, objectType=article, longId=730950, objectId=4c1de309500a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c1de309500a, replyNumber=0, likeNumber=80, createdTime=2022-07-02, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c1de309500a, moduleTitle=Cell Chemical Biology：上科大仓勇团队发现分子胶可增强PD-1抗体肿瘤免疫疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c1de309500a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577114, encodeId=d31e15e7114a8, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌, objectType=article, longId=729651, objectId=592de2965133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=592de2965133, replyNumber=0, likeNumber=123, createdTime=2022-06-17, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=592de2965133, moduleTitle=Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=592de2965133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577113, encodeId=e6f515e71131b, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, objectType=article, longId=293200, objectId=ccdc2932002c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccdc2932002c, replyNumber=0, likeNumber=105, createdTime=2022-01-01, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccdc2932002c, moduleTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccdc2932002c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577112, encodeId=369c15e711212, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性, objectType=article, longId=216279, objectId=b8872162e982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8872162e982, replyNumber=0, likeNumber=103, createdTime=2021-08-26, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8872162e982, moduleTitle=Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8872162e982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577111, encodeId=dfc815e711169, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, objectType=article, longId=215476, objectId=dc262154e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc262154e628, replyNumber=0, likeNumber=116, createdTime=2021-08-10, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc262154e628, moduleTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc262154e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577110, encodeId=38cc15e711070, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Clin Cancer Res：地西他滨联合抗PD-1抗体可有效改善进展/复发性霍奇金淋巴瘤患者预后, objectType=article, longId=208192, objectId=eef420819284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eef420819284, replyNumber=0, likeNumber=98, createdTime=2021-03-10, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eef420819284, moduleTitle=Clin Cancer Res：地西他滨联合抗PD-1抗体可有效改善进展/复发性霍奇金淋巴瘤患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eef420819284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577109, encodeId=aec815e7109ad, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Clin Cancer Res：PD-1抗体Geptanolimab治疗罕见肺泡软组织肉瘤的活性, objectType=article, longId=203074, objectId=6f8b2030e4ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f8b2030e4ae, replyNumber=0, likeNumber=103, createdTime=2020-11-09, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f8b2030e4ae, moduleTitle=Clin Cancer Res：PD-1抗体Geptanolimab治疗罕见肺泡软组织肉瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f8b2030e4ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577108, encodeId=164a15e71083d, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, objectType=article, longId=189508, objectId=d6db18950878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6db18950878, replyNumber=0, likeNumber=105, createdTime=2020-03-08, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6db18950878, moduleTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6db18950878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577107, encodeId=80e515e7107d4, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Nat Cancer：轻断食或能增强免疫治疗效果！科学家发现饥饿让非小细胞肺癌对PD-1抗体更敏感，有望解决免疫治疗耐药问题, objectType=article, longId=187321, objectId=fb1118e3216f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb1118e3216f, replyNumber=0, likeNumber=104, createdTime=2020-02-04, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb1118e3216f, moduleTitle=Nat Cancer：轻断食或能增强免疫治疗效果！科学家发现饥饿让非小细胞肺癌对PD-1抗体更敏感，有望解决免疫治疗耐药问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb1118e3216f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577106, encodeId=15f815e710680, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, objectType=article, longId=185383, objectId=415318538314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415318538314, replyNumber=0, likeNumber=110, createdTime=2019-12-30, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415318538314, moduleTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415318538314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577105, encodeId=62bd15e710587, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=PNAS：破解PD-1抗体促进癌症超进展之谜！日本科学家发现PD-1抗体可激活调节T细胞，导致癌症超进展, objectType=article, longId=165899, objectId=551416589938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=551416589938, replyNumber=0, likeNumber=94, createdTime=2019-05-13, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=551416589938, moduleTitle=PNAS：破解PD-1抗体促进癌症超进展之谜！日本科学家发现PD-1抗体可激活调节T细胞，导致癌症超进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=551416589938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577104, encodeId=1ce815e71042b, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Nature：抗癌效果或赶上PD-1抗体！科学家从人粪便中分离出11株菌株，不但抗癌效果惊人，且可大幅增强免疫检查点抑制剂效果, objectType=article, longId=160331, objectId=075e160331a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075e160331a8, replyNumber=0, likeNumber=122, createdTime=2019-02-19, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075e160331a8, moduleTitle=Nature：抗癌效果或赶上PD-1抗体！科学家从人粪便中分离出11株菌株，不但抗癌效果惊人，且可大幅增强免疫检查点抑制剂效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075e160331a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577103, encodeId=a4a515e7103c5, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=国产PD-1抗体药信迪利单抗注射液获批，治疗霍奇金淋巴瘤, objectType=article, longId=156924, objectId=eab61569248c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab61569248c, replyNumber=0, likeNumber=174, createdTime=2018-12-30, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab61569248c, moduleTitle=国产PD-1抗体药信迪利单抗注射液获批，治疗霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eab61569248c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577102, encodeId=1a7515e710291, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=国产PD-1抗体获批上市，预期价格更“亲民”, objectType=article, longId=156099, objectId=d37115609944, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d37115609944, replyNumber=0, likeNumber=97, createdTime=2018-12-20, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d37115609944, moduleTitle=国产PD-1抗体获批上市，预期价格更“亲民”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d37115609944)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577101, encodeId=cc1915e710138, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=国产PD-1抗体药物——君实生物特瑞普利单抗获批！, objectType=article, longId=156025, objectId=fb2f1560250e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb2f1560250e, replyNumber=0, likeNumber=105, createdTime=2018-12-19, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb2f1560250e, moduleTitle=国产PD-1抗体药物——君实生物特瑞普利单抗获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb2f1560250e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577100, encodeId=495415e7100c7, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=第二代PD-1抗体药物M7824寻求国内上市，肿瘤免疫治疗一片红海, objectType=article, longId=153783, objectId=db76153e83a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db76153e83a2, replyNumber=0, likeNumber=89, createdTime=2018-11-19, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db76153e83a2, moduleTitle=第二代PD-1抗体药物M7824寻求国内上市，肿瘤免疫治疗一片红海, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db76153e83a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577099, encodeId=9c8715e70990e, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=PD-1抗体替雷利珠单抗研发历程, objectType=article, longId=152278, objectId=22631522e871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22631522e871, replyNumber=0, likeNumber=128, createdTime=2018-10-31, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22631522e871, moduleTitle=PD-1抗体替雷利珠单抗研发历程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22631522e871)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577098, encodeId=c94b15e709847, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=王峰教授：PD-１抗体虽屡获奇效，耐药后怎么办？, objectType=article, longId=150126, objectId=b51315012680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b51315012680, replyNumber=0, likeNumber=94, createdTime=2018-10-02, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b51315012680, moduleTitle=王峰教授：PD-１抗体虽屡获奇效，耐药后怎么办？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b51315012680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577097, encodeId=3be415e70971d, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=PD-1抗体引起的不良反应预示着会有更长的生存期, objectType=article, longId=147516, objectId=5cee14e51627, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cee14e51627, replyNumber=0, likeNumber=110, createdTime=2018-08-29, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cee14e51627, moduleTitle=PD-1抗体引起的不良反应预示着会有更长的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cee14e51627)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1抗体

2020-05-29

梅斯管理员

#黑色素瘤# #结直肠癌# #PD-1抗体# #CTLA-4抗体# #双免疫治疗#

大咖谈 | 双免疫联合治疗的机制和研究进展

2024-07-02发表于上海

1249857fm37暂无昵称

#PD-1抗体#

Cell Chemical Biology：上科大仓勇团队发现分子胶可增强PD-1抗体肿瘤免疫疗效

2022-07-02

1249857fm37暂无昵称

#PD-1抗体#

Clin Cancer Res：抗PD-1抗体联合多激酶抑制剂治疗晚期胃癌

2022-06-17

1249857fm37暂无昵称

#PD-1抗体#

今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测

2022-01-01

1249857fm37暂无昵称

#PD-1抗体#

Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性

2021-08-26

1249857fm37暂无昵称

#PD-1抗体#

Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效

2021-08-10

1249857fm37暂无昵称

#PD-1抗体#

Clin Cancer Res：地西他滨联合抗PD-1抗体可有效改善进展/复发性霍奇金淋巴瘤患者预后

2021-03-10

1249857fm37暂无昵称

#PD-1抗体#

Clin Cancer Res：PD-1抗体Geptanolimab治疗罕见肺泡软组织肉瘤的活性

2020-11-09

1249857fm37暂无昵称

#PD-1抗体#

百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代

2020-03-08

1249857fm37暂无昵称

#PD-1抗体#

Nat Cancer：轻断食或能增强免疫治疗效果！科学家发现饥饿让非小细胞肺癌对PD-1抗体更敏感，有望解决免疫治疗耐药问题

2020-02-04

1249857fm37暂无昵称

#PD-1抗体#

百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了

2019-12-30

1249857fm37暂无昵称

#PD-1抗体#

PNAS：破解PD-1抗体促进癌症超进展之谜！日本科学家发现PD-1抗体可激活调节T细胞，导致癌症超进展

2019-05-13

智慧医人

#PD-1抗体#

Nature：抗癌效果或赶上PD-1抗体！科学家从人粪便中分离出11株菌株，不但抗癌效果惊人，且可大幅增强免疫检查点抑制剂效果

2019-02-19

1249857fm37暂无昵称

#PD-1抗体#

国产PD-1抗体药信迪利单抗注射液获批，治疗霍奇金淋巴瘤

2018-12-30

1249857fm37暂无昵称

#PD-1抗体#

国产PD-1抗体获批上市，预期价格更“亲民”

2018-12-20

1249857fm37暂无昵称

#PD-1抗体#

国产PD-1抗体药物——君实生物特瑞普利单抗获批！

2018-12-19

1249857fm37暂无昵称

#PD-1抗体#

第二代PD-1抗体药物M7824寻求国内上市，肿瘤免疫治疗一片红海

2018-11-19

1249857fm37暂无昵称

#PD-1抗体#

PD-1抗体替雷利珠单抗研发历程

2018-10-31

1249857fm37暂无昵称

#PD-1抗体#

王峰教授：PD-１抗体虽屡获奇效，耐药后怎么办？

2018-10-02

1249857fm37暂无昵称

#PD-1抗体#

PD-1抗体引起的不良反应预示着会有更长的生存期

2018-08-29